KOSDAQBiotech & Pharma424870

ImmuneOncia Therapeutics

₩3,440▲ 0.73%2026-10-02 close

Market Cap

₩314.9B

Turnover

₩4.1B

Volume

1.2M

Shares out.

91.4M

PER

—

PBR

—

EPS

-₩398

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Immuno-Oncology Progress Meets Funding Strain

ImmuneOncia Therapeutics, a subsidiary of Yuhan Corporation, is pursuing what would be Korea's first commercialized immuno-oncology drug through its PD-L1 antibody danburstotug (IMC-001) and CD47 antibody IMC-002, but as a pre-revenue clinical-stage biotech it faces both encouraging trial data and recurring capital-raising pressure.

1
IMC-001 (danburstotug) posted a 79% objective response rate and 63% complete response rate in a Phase 2 trial for relapsed/refractory NK/T-cell lymphoma.
2
The drug received Korea's orphan drug designation in January 2026, opening a pathway to commercialization without a Phase 3 trial.
3
A roughly KRW 120 billion rights offering decided in February 2026 saw its final proceeds shrink to about KRW 81.8 billion after the issue price was cut amid a falling share price.
4
Consolidated 2025 revenue was only about KRW 111 million, while both the operating loss and net loss widened sharply from a year earlier.
5
On a quarterly basis, the operating loss narrowed sequentially from the third quarter of 2025 through the second quarter of 2026.

Business structure

ImmuneOncia Therapeutics was founded in 2016 as a joint venture between Yuhan Corporation and US-based Sorrento Therapeutics, and Yuhan became the controlling shareholder after Sorrento entered court-led restructuring and its stake was acquired.

The company's core assets are antibody-based immune checkpoint inhibitors targeting T-cells and macrophages, with the PD-L1 antibody danburstotug (IMC-001) and next-generation CD47 antibody IMC-002 forming its two clinical-stage pillars.

IMC-001 is in a domestic Phase 2 trial targeting NK/T-cell lymphoma and tumor mutation burden-high (TMB-H) solid tumors, and under a distribution agreement Yuhan would serve as the exclusive domestic distributor upon commercialization.

IMC-002 was out-licensed to China's 3D Medicine in 2021 for Greater China rights, in a deal reported to be worth up to $470.5 million including an $8 million upfront payment.

This antibody is regarded as having an improved safety profile due to reduced binding to normal cells, and is in Phase 1b trials for triple-negative breast cancer, hepatocellular carcinoma, and biliary tract cancer.

The company also holds preclinical follow-on candidates including the CD47xPD-L1 bispecific IMC-201 and the PD-L1xTIGIT bispecific IMC-202. Its business model centers on generating revenue through early-stage licensing deals, while pursuing a dual-track strategy of also directly commercializing IMC-001 domestically.

In terms of competitive positioning, the PD-(L)1 immuno-oncology market is dominated by Merck's Keytruda, and the CD47 class has seen major global pharma players such as AbbVie, Pfizer, and Gilead discontinue programs due to toxicity issues, so ImmuneOncia is positioning its rare-disease indications and improved safety profile as points of differentiation.

Earnings trend

Quarterly revenue · Operating profit

25Q2₩0-₩10.6B25Q3₩0-₩9.6B25Q4₩0-₩5.8B26Q1₩0-₩4.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩700M-₩12.6B2024₩100M-₩28B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	—	—	—
2025Q3	₩0	-₩10.6B	—
2025Q4	₩0	-₩9.6B	—
2026Q1	₩0	-₩5.8B	—
2026Q2	₩0	-₩4.3B	—

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2024	₩700M	-₩12.6B	-₩5.7B	−1924.8%	−29.3%	34.9%
2025	₩100M	-₩28B	-₩27.4B	−25182.0%	−96.3%	16.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Consolidated revenue in 2025 came to about KRW 112 million, down sharply from KRW 655 million in 2024. In contrast, the operating loss widened from KRW 12.6 billion in 2024 to KRW 28.0 billion in 2025, and the net loss attributable to owners expanded from KRW 5.7 billion to KRW 27.4 billion over the same period.

Given the near-absence of a revenue base typical of a clinical-stage company, the operating margin registered at -25,182%, making the ratio of limited analytical use on its own.

Looking at the most recent four quarters (Q3 2025 through Q2 2026), however, the operating loss narrowed sequentially from KRW 10.6 billion to KRW 9.6 billion, KRW 5.8 billion, and KRW 4.3 billion, while the net loss attributable to owners likewise shrank from KRW 10.4 billion to KRW 9.4 billion, KRW 5.6 billion, and KRW 3.9 billion.

The sum of net losses to owners over these four quarters was about KRW 29.3 billion, underscoring that substantial losses persisted despite the improving quarterly trend.

On the balance sheet, total equity rose from KRW 19.4 billion in 2024 to KRW 28.4 billion in 2025, a change largely attributable to the roughly KRW 33 billion raised through the company's May 2025 KOSDAQ initial public offering.

Total liabilities fell from KRW 6.8 billion to KRW 4.7 billion, lowering the debt ratio from 34.9% to 16.6%, yet operating cash flow deteriorated from negative KRW 14.7 billion in 2024 to negative KRW 22.8 billion in 2025, indicating a faster pace of cash consumption.

Overall, the combination of a thin revenue base and rising R&D spending drove larger absolute losses, even as the more recent quarterly trend points to a gradual narrowing of losses.

Industry analysis

The global immuno-oncology market is described as roughly KRW 80 trillion in size, within which Merck's Keytruda alone generated about KRW 45 trillion in sales last year, giving it an overwhelmingly dominant position.

While PD-(L)1 class antibodies already face intense competition across major approved indications such as lung cancer, melanoma, and bladder cancer, ImmuneOncia has chosen to first target NK/T-cell lymphoma, a rare and hard-to-treat blood cancer lacking a standard of care, as a way to lower its market entry barrier.

The CD47 class of immunotherapies was once seen as a potential successor to PD-1/PD-L1 mechanisms, but industry-wide enthusiasm has cooled after global pharma majors including AbbVie, Pfizer, and Gilead discontinued programs due to hematologic toxicity issues.

Against this backdrop, ImmuneOncia's IMC-002 is credited with an improved safety profile through reduced normal-cell binding, and it competes for global licensing deals against CD47 antibodies developed by Chinese biotechs such as ImmuneOnco and Akeso Biopharma.

More broadly, heightened regulatory scrutiny of pre-revenue listings and follow-on fundraising in Korea's biotech sector means technology-special-listing companies face a higher bar from the market when raising additional capital.

Within this environment, ImmuneOncia is seen as relatively well positioned on the R&D funding side given that its controlling shareholder is Yuhan, a major established pharmaceutical company.

Outlook

After receiving Korea's orphan drug designation for danburstotug from the Ministry of Food and Drug Safety in January 2026, ImmuneOncia secured a pathway to pursue commercialization without a Phase 3 trial, and it has adjusted its plan to move up the domestic filing timeline from its earlier target of after 2030.

The company has stated a goal of filing for marketing approval in the first quarter of 2029 and achieving commercialization by 2031, with funding needs expected to be supplemented by licensing revenue anticipated from 2026 onward.

On the manufacturing side, the company said it completed a commercial technology transfer for danburstotug with global CDMO Lonza, signaling that commercial-readiness preparations are underway.

IMC-002 remains in Phase 1b trials across triple-negative breast cancer, hepatocellular carcinoma, and biliary tract cancer, and the company has said it is separately pursuing a global out-licensing deal targeting North America and Europe with a 2026 goal.

On the financing side, the February 2026 rights offering saw its final proceeds reduced from the original plan after the issue price was reset lower amid a falling share price, but the offering was completed without a residual-share burden as the existing shareholder subscription rate exceeded 104%.

Because the final amount raised was smaller than planned, the company said it reprioritized its fund allocation toward higher-priority items such as manufacturing, quality control, and regulatory response.

Going forward, the key things to watch are whether IMC-002 secures an actual global licensing agreement and whether IMC-001's commercialization funding can be executed as planned without requiring another capital raise.

Valuation

PER

—

PBR

—

ROE

-39.7%

EPS

-₩398

BPS

—

Dividend per share

₩0

As ImmuneOncia has yet to generate net income, earnings-based valuation metrics such as a price-to-earnings ratio cannot be computed.

The share price trades at a premium to the company's self-calculated net asset value, a pattern common among listed biotechs where expectations for future licensing deals or clinical progress are priced in ahead of the current book value.

Because the recent large-scale rights offering increased the share count, the baseline for per-share metrics going forward has shifted, so comparisons against past valuation levels warrant caution.

Dividends are not paid, consistent with most clinical-stage biotechs including this one, making dividend-yield-based comparisons of limited use for this stock.

Ultimately, valuation for this name appears to hinge less on current earnings than on clinical pipeline progress, the conclusion of licensing negotiations, and the scale of any additional capital that may be needed before commercialization.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Clinical Data Momentum

IMC-001 posted a 79% objective response rate and 63% complete response rate in a Phase 2 trial for relapsed/refractory NK/T-cell lymphoma, with progression-free survival reported to be substantially improved versus standard chemotherapy.

In January 2026 the drug received orphan drug designation, securing a regulatory pathway toward approval without a Phase 3 trial. IMC-002 also showed a 60% response rate in patients with high CD47 expression, pointing to potential for a biomarker-based patient selection strategy.

Proven Licensing Track Record

IMC-002 was already out-licensed to China's 3D Medicine in 2021 for Greater China rights, in a deal reported to total up to $470.5 million including an $8 million upfront payment.

Building on this track record, the company has said it is pursuing an additional global licensing deal targeting North America and Europe with a 2026 goal. Completing a manufacturing technology transfer with global CDMO Lonza for danburstotug also demonstrates progress in commercialization readiness.

Continued Parent Company Backing

Yuhan Corporation has invested continuously in ImmuneOncia since its founding and strengthened its position as controlling shareholder by acquiring Sorrento's stake following Sorrento's 2023 bankruptcy.

After the 2026 rights offering drew criticism, Yuhan raised its subscription commitment from KRW 10 billion to KRW 15 billion, signaling a degree of accountable ownership. Potential collaboration such as combination therapy with Yuhan's own oncology portfolio has also been cited as a basis for longer-term support.

Bear factors

Recurring Large-Scale Fundraising Burden

In February 2026, less than a year after its listing, the company decided on a rights offering of roughly KRW 120 billion, more than three times its original IPO proceeds, drawing minority shareholder backlash and a request for a revised filing from the Financial Supervisory Service.

Subsequent share price declines lowered the final issue price, reducing the amount actually raised by roughly 32% versus the original plan. With commercialization funding now smaller than initially outlined, some industry observers have said the possibility of another capital raise cannot be entirely ruled out.

Absent Revenue Base and Ongoing Cash Burn

Consolidated 2025 revenue was just over KRW 100 million, meaning operating revenue alone cannot cover R&D spending. Operating cash flow actually worsened, from negative KRW 14.7 billion in 2024 to negative KRW 22.8 billion in 2025.

With at least several years remaining before commercialization, the pace of cash consumption during that period remains a key variable for financial stability.

Intensifying Competition and Technical Uncertainty

The PD-(L)1 immuno-oncology market is overwhelmingly dominated by Merck's Keytruda, making it difficult for a new entrant to secure a foothold.

In the CD47 class, precedents of program discontinuation by global pharma majors including AbbVie, Pfizer, and Gilead due to hematologic toxicity have left broader industry caution around the mechanism itself.

Competing biotechs such as China's ImmuneOnco and Akeso Biopharma are also pursuing CD47 antibody licensing deals, intensifying competition to secure global partners.

Risk factors

Clinical and Regulatory Risk

Orphan drug designation does not guarantee a Phase 3 exemption or expedited approval, as the final determination rests with regulatory discretion. Follow-on pipeline candidates such as IMC-002 remain at an early clinical stage and require further accumulation of efficacy and safety data.

Global clinical and approval timelines could also be delayed depending on the outcome of discussions with overseas regulators.

Financing and Dilution Risk

Because the 2026 rights offering raised less than originally planned, the possibility that additional financing will be needed during commercialization preparations cannot be ruled out. Any further rights offering or convertible bond issuance could again dilute existing shareholders.

The willingness and scale of future participation by controlling shareholder Yuhan is also a variable that warrants continued monitoring.

Partnering Failure Risk

If the global (North America and Europe) out-licensing deal for IMC-002 that the company has targeted for 2026 does not materialize as planned, expected licensing revenue could be delayed or fail to arrive. This could in turn affect the plan to supplement commercialization funding.

Discussions with prospective global partners are ongoing, but the timing and terms of any deal remain unconfirmed.

What to watch next

Around October 2026
Watch whether additional clinical data for IMC-001 and IMC-002 are presented at international conferences such as ESMO.
Mid-November 2026 (expected Q3 earnings disclosure)
Check whether the third-quarter 2026 consolidated results continue the recent trend of narrowing operating and net losses, and whether the pace of cash burn eases.
Second half of 2026
Confirm whether the company's targeted global licensing negotiations for IMC-002 in North America and Europe actually result in a signed agreement.
From the second half of 2026 onward
Monitor manufacturing and quality-control readiness following the commercial technology transfer with Lonza, as well as the pace at which rights-offering proceeds are used and whether additional fundraising becomes necessary.

Overall view

ImmuneOncia benefits from its position as a Yuhan Corporation subsidiary, strong Phase 2 clinical data for IMC-001, and a commercialization pathway secured through orphan drug designation.

At the same time, as a clinical-stage company with almost no revenue base, it continues to post large losses, and uncertainty around financing has been underscored by a large rights offering conducted within a year of listing that ultimately raised less than planned.

The narrowing trend in operating and net losses over the past four quarters can be read as a positive sign, though it should be noted that losses in the tens of billions of won per quarter still persist.

Going forward, the key variables for assessing the company's value are likely to be whether a global licensing agreement for IMC-002 is concluded and whether IMC-001's commercialization preparations can proceed as planned without requiring further capital raises.

Tracking the clinical, regulatory, and partnering progress of both pipelines in a balanced way should help in understanding this stock.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.